When cancer starts in the uterus, it is called uterine cancer. The uterus is the pear-shaped organ in a woman's pelvis (the area below your stomach and in between your hip bones). The uterus, also called the womb, is where the baby grows when a woman is pregnant. The most common type of uterine cancer is also called endometrial cancer because it forms in the lining of your uterus, called the endometrium.
When uterine cancer is found early, treatment is most effective. The most common sign of uterine cancer is bleeding that is not normal for you because of when it happens or how heavy it is. This could mean bleeding, even a little bit, after you have gone through menopause; periods that are longer than seven days; bleeding between periods; or any other bleeding that is longer or heavier than is normal for you.
Other symptoms, such as pain or pressure in your pelvis, also may occur if you have uterine cancer. If you have any of these symptoms, talk to your doctor, nurse, or other health care professional right away. They may be caused by something other than cancer, but the only way to know is to see your health care professional.
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer postoperative complications, the researchers say.
Minimally invasive gynecologic surgeries have advantages for patients, including shorter hospital stays, quicker recoveries, and less pain. However, power morcellation, a technique which cuts the uterus or fibroid into small pieces in order to extract them from the abdomen through a small incision, may worsen a woman's prognosis if a cancer is morcellated unintentionally.
The Endocrine Society today issued a Clinical Practice Guideline (CPG) on identifying women who are candidates for treatment of menopausal symptoms and selecting the best treatment options for each individual.
University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease.
University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease. By more selectively targeting cancer cells, this method offers a strategy to reduce the length of and physical toll associated with current treatments.
About 3% of colorectal cancers are due to Lynch syndrome, an inherited cancer susceptibility syndrome that predisposes individuals to various cancers. Close blood relatives of patients with Lynch syndrome have a 50% chance of inheritance. The role that PMS2 genetic mutations play in Lynch syndrome has been underestimated in part due to technological limitations.
The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.
Juniper Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, announced today the first patient has been enrolled in a Phase II clinical trial of COL-1077, a 10% lidocaine bioadhesive gel that is intended as an acute-use anesthetic during minimally invasive gynecologic procedures.
More than one-third of counties in the Unites States are located more than 50 miles from the nearest gynecologic oncologist, making access to specialty care for ovarian and other gynecologic cancers difficult for nearly 15 million women. While most of these "low access" counties are located in the Mountain-West and Midwest regions, the findings of a recent study from researchers at the Perelman School of Medicine at the University of Pennsylvania also reveal that 47 states have at least one county located more than 50 miles from the nearest gynecologic oncologist.
Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen.
In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.
Researchers at Uppsala University have, together with researchers from Turku and Bergen, discovered a new biomarker which makes it possible to identify women with uterine cancer who have a high risk of recurrence.
Caris Life Sciences today announced the presentation of a study that found drugs targeting specific pathways may have potentially significant benefit in a select subset of patients with uterine cancer. The study results were highlighted today in an oral presentation in a Plenary Session at the Society of Gynecologic Oncology 2015 Annual Meeting on Women's Cancer in Chicago, Ill.
A national group of researchers, medical bodies and charities, led by The University of Manchester is looking for help in setting the top priorities for fighting womb cancer, with a survey launched today (23 March 2015).
Our research into gynaecological oncology focuses around understanding mechanisms of how genes are regulated or how they become dysregulated in a disease; and also the effects that has on the surface of the endometrium and also the function of the ovaries...
The U.S. Food and Drug Administration is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids, which is in keeping with Kalorama Information's view that in the female health market there is much room for improvement both in the development of products and the treatment of diseases.
Genetic screening services for rural and underserved populations will expand from six to 22 counties in North Texas under a $1.5 million grant from the Cancer Prevention and Research Institute of Texas to UT Southwestern Medical Center.
Surgeon Teresa Rutledge, MD, recently received the National Cancer Institute's Cancer Clinical Investigator Team Leadership Award. Only 11 people nationwide received the award this year. Dr. Rutledge is the third faculty member in the history of the University of New Mexico Cancer Center to be recognized with this honor.
Among women undergoing a minimally invasive hysterectomy using electric power morcellation, uterine cancers were present in 27 per 10,000 women at the time of the procedure, according to a study published by JAMA.
A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects that deter some women from taking it, according to new Northwestern Medicine- research.